Sanofi improves outlook on strength of bestseller Dupixent

Sanofi improves outlook on strength of bestseller Dupixent

In the first nine months of the year, revenue reached 32.3 billion euros
In the first nine months of the year, revenue reached 32.3 billion euros. Photo: Thomas SAMSON / AFP
Source: AFP

French drug maker Sanofi has revised its outlook for 2022 upwards after reporting strong sales growth in the third quarter on Friday.

While Sanofi faced struggles in producing a jab against Covid, its Dupixent drug, which treats conditions including asthma and eczema, has been a huge success.

In Q3, sales of Dupixent exceeded the two billion euros mark for the first time, Sanofi said in a statement.

The pharmaceutical giant was also boosted by nearly two billion euros of sales for its flu vaccines, as many countries prepare for the peak winter flu season.

Sanofi said between July and the end of September, net profit fell 10 percent to two billion euros ($2 billion) due to impairments.

But without exceptional items net profit jumped 32 percent to 3.6 billion euros, higher than expected by analysts.

Read also

Air France-KLM Q3 turnover above pre-Covid levels

PAY ATTENTION: Subscribe to Digital Talk newsletter to receive must-know business stories and succeed BIG!

And in the first nine months of the year, revenue reached 32.3 billion euros -- an increase of more than 16 percent.

Sanofi now expects earnings per share (EPS) -- a measure of a company's profitability -- of around 16 percent for this year, up from earlier predictions.

Source: AFP

Online view pixel